The first randomized, double-blind, placebo-controlled trial of Paxlovid for Long COVID, testing a 15-day course in patients with moderate-to-severe PASC symptoms. Treatment was generally safe but did not produce a statistically significant improvement in targeted symptoms versus placebo.
Treatment & Management
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial
June 7, 2024
The first randomized, placebo-controlled Paxlovid trial for Long COVID found the drug safe but without statistically significant symptom improvement.
Save For Later
Email yourself a link to this article.
Saved. Check your email app.
Something didn't go through — try again.